P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

After dozens of clinical trials, there are still no effective vaccines against Staphylococcus ... IL-10 in response to S. aureus shuts down the ability of helper T cells to fight the pathogen.

It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over two years since we heard anything official about the game. From what we've ...

S. aureus bacteria, which enter host cells of the same cell population via the rapid pathway, cause a distinct infection outcome with altered phagosome maturation, bacterial translocation to host ...

The manuscript by Rühling et al analyzes the mode of entry of S. aureus into mammalian cells in culture. The authors propose a novel mechanism of rapid entry that involves the release of calcium from ...